Ceragenix Pharmaceuticals, Inc., today announced that Promius Pharma, LLC, a wholly owned subsidiary of Dr. Reddy’s Laboratories (“DRL”) launched its first product, EpiCeram® Skin Barrier Emulsion. EpiCeram Emulsion is a novel prescription therapy for the treatment of atopic dermatitis, a skin disease that affects more than 15 million Americans at an estimated cost of $1 billion annually. Promius Pharma launched EpiCeram Emulsion this week at the 27th Annual Fall Clinical Dermatology Conference, attended by over 400 dermatologists and healthcare providers.
In November 2007, Ceragenix entered into an exclusive distribution and supply agreement with DRL for the commercialization of EpiCeram in the United States (the “DRL Agreement”). Under the terms of the DRL Agreement, Ceragenix is responsible for the manufacturing and supplying of the product while DRL is responsible for the distribution, marketing and sales.
“We are very excited about the launch of EpiCeram” said Steven Porter, Chairman and Chief Executive Officer of Ceragenix. “This represents the commercialization of our first product and is the culmination of a lot of hard work by the Ceragenix and Promius teams. We are very impressed with the dermatology sales and marketing team assembled by Promius and are confident in their ability to make EpiCeram a commercial success. Now that EpiCeram has been launched, we will be focusing our efforts on furthering the development of our pipeline.”
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins™ or (“CSAs”) for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin and Cerashield products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of two topical creams--EpiCeram and NeoCeram. EpiCeram has been cleared for marketing by the United States Food and Drug Administration (“FDA”) while we plan to develop NeoCeram as an OTC product
Contact:
Ceragenix Pharmaceuticals, Inc.
Steven Porter, Chairman and CEO, 720-946-6440
Source: Ceragenix Pharmaceuticals, Inc.
In November 2007, Ceragenix entered into an exclusive distribution and supply agreement with DRL for the commercialization of EpiCeram in the United States (the “DRL Agreement”). Under the terms of the DRL Agreement, Ceragenix is responsible for the manufacturing and supplying of the product while DRL is responsible for the distribution, marketing and sales.
“We are very excited about the launch of EpiCeram” said Steven Porter, Chairman and Chief Executive Officer of Ceragenix. “This represents the commercialization of our first product and is the culmination of a lot of hard work by the Ceragenix and Promius teams. We are very impressed with the dermatology sales and marketing team assembled by Promius and are confident in their ability to make EpiCeram a commercial success. Now that EpiCeram has been launched, we will be focusing our efforts on furthering the development of our pipeline.”
About Ceragenix
Ceragenix Pharmaceuticals, Inc. is a medical device company focused on infectious disease and dermatology. The Company has two base technology platforms; Ceragenins™ or (“CSAs”) for treatment of infectious disease and Barrier Repair for the treatment of dermatological disorders including atopic dermatitis, neonatal skin disorders and others. Ceragenin compounds are active against a broad range of gram positive and negative bacteria. We have used our Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. All Ceragenin and Cerashield products are currently in the developmental stage. Ceragenix's patented Barrier Repair technology, invented by Dr. Peter Elias, is the platform for the development of two topical creams--EpiCeram and NeoCeram. EpiCeram has been cleared for marketing by the United States Food and Drug Administration (“FDA”) while we plan to develop NeoCeram as an OTC product
Contact:
Ceragenix Pharmaceuticals, Inc.
Steven Porter, Chairman and CEO, 720-946-6440
Source: Ceragenix Pharmaceuticals, Inc.
0 comments:
Post a Comment